NCT07135349 - A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

June 7, 2026

Study Completion Date

May 8, 2028

Conditions

Chronic Hepatitis B

Interventions

DRUG

BW-20507 with/without NUC

• BW-20507 with/without NUCs will be administrated for 48 weeks

DRUG

BW-20507 with/without NUC, Peg-IFNa

• BW-20507 with/without NUC will be administrated for 48 weeks, Peg-IFNa will be administrated.

Trial Locations (18)

22100

Argo Investigative Site, Xuzhou

100015

Argo Investigative Site, Beijing

213000

Argo Investigative Site, Changzhou

230022

Argo Investigative Site, Hefei

310000

Argo Investigative Site, Hangzhou

330000

Argo Investigative Site, Nanchang

350000

Argo Investigative Site, Fuzhou

400000

Argo Investigative Site, Chongqing

510515

Argo Investigative Site, Guangzhou

518000

Argo Investigative Site, Shenzhen

563000

Argo Investigative Site, Zunyi

610041

Argo Investigative Site, Chengdu

2000001

Argo Investigative Site, Shanghai

Unknown

Argo Investigative Site, Sichuan

Argo Investigative Site, Chongqing

Argo Investigative Site, Jiangxi

Argo Investigative Site, Zhejiang

All Listed Sponsors

lead

Shanghai Argo Biopharmaceutical Co., Ltd.

INDUSTRY